This article is more than 5 years old. Information may no longer be current.

Valeant Pharmaceuticals announces FDA approval of Retin-A Micro 0.08% for acne vulgaris

Valeant Pharmaceuticals International announced the FDA has approved its supplemental new drug application for its tretinoin gel microsphere 0.08% for treating acne vulgaris.

“This gives health care providers and patients a new option for the topical treatment of acne vulgaris,” J. Michael Pearson, chairman and chief executive officer of Valeant, said in a press release. “This new strength … should be a welcome alternative to current strengths. We look forward to launching 0.08% Retin-A Micro in the near future.”

Skin pain, pruritus, skin irritation, subcutaneous irritation, pharyngitis and erythema are common adverse reactions reported with Retin-A Micro treatment, according to the release.